TrialEuropean urology2023

Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605.

Peter C Black et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.